The company now expects $650 million to $700 million in revenue ... paired with milestone payments and royalties for 20 years ...
The company now expects $650 million to $700 million in revenue for the year, down from previous guidance of $700 million to ...
BofA lowered the firm’s price target on Novavax (NVAX) to $12 from $14 and keeps a Neutral rating on the shares. The company announced ...
Eric Joseph has given his Sell rating due to a combination of factors affecting Novavax’s current and future performance. One major concern is the company’s underwhelming market share for its COVID ...
Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced ...
Good morning and welcome to Novavax' Third Quarter 2024 Financial Results and Operational Highlights Conference Call. All ...
Novavax has made a smaller splash in the U.S. Covid-19 vaccine market than it had hoped. But it's betting on licensing deals ...
Novavax Inc. closed $15.40 short of its 52-week high ($23.86), which the company achieved on June 6th. Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated ...
GlobalData on MSN23h
FDA clears Novavax to resume trials of Covid-19 and flu combo vaccineNovavax has received the green light from the US Food and Drug Administration (FDA) to resume clinical trials for its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback